SLSBio(Specialty Lab Solution Bio)에스엘에스바이오
246250 · KOSDAQ · ₩246250 · 에스엘에스바이오
₩1,969 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −89.0% | −48.6% | 27.1% | 34.5% | 39.2% | 26.4% |
| Operating margin | −175.1% | −103.0% | 3.4% | 11.4% | 22.5% | 5.2% |
| Net margin | −194.7% | −123.1% | 4.0% | 15.9% | 26.3% | 0.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −27.5% | −52.4% | −7.2% | −16.1% | +30.4% | — |
| Operating income growth | −23.3% | −1,527.4% | −72.1% | −57.5% | +468.6% | — |
| Net income growth | −14.7% | −1,561.1% | −76.6% | −49.3% | +4,781.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −83.9% | −48.7% | 2.6% | 14.2% | 54.2% | 1.6% |
| Return on assets | −53.7% | −35.6% | 2.0% | 9.7% | 25.4% | 0.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 68.2% | 47.1% | 30.7% | 32.5% | 75.3% | 182.1% |
| Net debt to equity | −23.6% | — | −61.4% | −69.5% | −22.8% | 10.5% |
| Current ratio | 138.1% | 285.0% | 663.9% | 677.0% | 296.5% | 110.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: SLSBio(Specialty Lab Solution Bio) / 에스엘에스바이오 / 246250 / KRX:246250
Source: KRX statistical information